Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts, 02115.
Department of Surgery, Harvard Medical School and Boston Children's Hospital, Boston, Massachusetts, 02115.
Cytometry A. 2019 Aug;95(8):843-853. doi: 10.1002/cyto.a.23848. Epub 2019 Jul 11.
A rapid, high-throughput, and quantitative method for cell entry route characterization is still lacking in nanomedicine research. Here, we report the application of imaging flow cytometry for quantitatively analyzing cell entry routes of actively targeted nanomedicines. We first engineered ICAM1 antibody-directed fusogenic nanoliposomes (ICAM1-FusoNLPs) and ICAM1 antibody-directed endocytic nanolipogels (ICAM1-EndoNLGs) featuring highly similar surface properties but different cell entry routes: receptor-mediated membrane fusion and receptor-mediated endocytosis, respectively. By using imaging flow cytometry, we characterized their intracellular delivery into human breast cancer MDA-MB-231 cells. We found that ICAM1-FusoNLPs mediated a 2.8-fold increased cell uptake of fluorescent payload, FITC-dextran, with a 2.4-fold increased intracellular distribution area in comparison with ICAM1-EndoNLGs. We also investigated the effects of incubation time and endocytic inhibitors on the cell entry routes of ICAM1-FusoNLP and ICAM1-EndoNLG. Our results indicate that receptor-mediated membrane fusion is a faster and more efficient cell entry route than receptor-mediated endocytosis, bringing with it a significant therapeutic benefit in a proof-of-principle nanomedicine-mediated siRNA transfection experiment. Our studies suggest that cell entry route may be an important design parameter to be considered in the development of next-generation nanomedicines. © 2019 International Society for Advancement of Cytometry.
一种快速、高通量且定量的细胞进入途径表征方法在纳米医学研究中仍然缺乏。在这里,我们报告了成像流式细胞术在定量分析主动靶向纳米药物细胞进入途径中的应用。我们首先设计了具有高度相似表面特性但不同细胞进入途径的 ICAM1 抗体导向融合纳米脂质体(ICAM1-FusoNLPs)和 ICAM1 抗体导向内吞纳米脂质体(ICAM1-EndoNLGs):受体介导的膜融合和受体介导的内吞作用。通过使用成像流式细胞术,我们对它们进入人乳腺癌 MDA-MB-231 细胞的细胞内递呈进行了特征描述。我们发现,与 ICAM1-EndoNLG 相比,ICAM1-FusoNLPs 介导的荧光有效负载 FITC-葡聚糖的细胞摄取增加了 2.8 倍,细胞内分布面积增加了 2.4 倍。我们还研究了孵育时间和内吞抑制剂对 ICAM1-FusoNLP 和 ICAM1-EndoNLG 细胞进入途径的影响。我们的结果表明,受体介导的膜融合是一种比受体介导的内吞作用更快、更有效的细胞进入途径,在 siRNA 转染实验中具有显著的治疗益处。我们的研究表明,细胞进入途径可能是下一代纳米药物开发中需要考虑的重要设计参数。